Published in Cancer Weekly, May 17th, 2005
Many tumors grow under conditions of reduced oxygen tension (hypoxia). This makes them insensitive or resistant to treatment by radiation (X-rays). EOquin, a pro-drug, becomes a cytotoxic alkylating agent in the presence of an enzyme that is present in greater amounts in hypoxic cancer cells. In clinical studies conducted to date, EOquin has shown good efficacy in treating patients with refractory...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.